Introduction
Surgery exposes patients to a risk of venous thromboembolism (VTE) and bleeding. VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE), which represent serious and sometimes fatal consequences of surgery. Therefore, optimizing treatment plans to reduce VTE risk while also minimizing bleeding risk is important to patients and the healthcare system. The goal of this Canadian Urological Association (CUA) guideline is to provide a structured approach to the prevention of perioperative thromboembolic events that may be applied in Canada.
In this guideline, two forms of perioperative VTE prophylaxis are considered. The first is prophylaxis used for primary prevention VTE for patients undergoing surgery. The second is management of an anticoagulant or antiplatelet agent used for treatment or as a form of secondary prevention during the perioperative period. The CUA thromboprophylaxis guideline panel feels that it is important for urologists to be engaged in the discussion and management in each of these situations. The panel recognizes that in many clinical contexts, other specialists, including internists, cardiologists, neurologists, and hematologists, may also be involved in this aspect of patient care. The guidance provided in this document is intended to help urologists engage with their patients and colleagues in a collaborative context. The guidance provided in this document is intended to reflect best practice for the usual case for a specific surgery and patient population. This guideline is not intended for unusual conditions or circumstances, which are typically rare, and should be addressed involving appropriate specialists on a caseby-case basis.
Decisions regarding thromboprophylaxis involve a tradeoff, in which the intended purpose is to decrease the risk of VTE while recognizing that thromboprophylaxis also increases the risk of bleeding. A systematic review and metaanalysis of randomized placebo-controlled trials performed for the American College of Chest Physicians VTE guideline reported that VTE prophylaxis decreases the relative risk of VTE by 50% and increases the relative risk of bleeding by 50%. 1 In cases where the risk of VTE is high and the bleeding risk is low, VTE prophylaxis is usually warranted because the net benefit is favourable. When the risk of VTE is low and the bleeding risk is high, VTE prophylaxis may be harmful and is usually not warranted. In many cases, the tradeoff between VTE prevention and bleeding risk may be close and the "most favourable" approach to VTE prophylaxis is less clear. In these situations, individual patient values and preferences must be considered to determine the best management plan (Fig. 1) .
Proper evaluation of the risks and benefits of thromboprophylaxis for urological surgery requires both procedure-and patient-specific knowledge. [2] [3] [4] To judge the net benefit of VTE prophylaxis, one must know the surgery-specific baseline risk of VTE and major bleeding. For a given procedure the baseline risk of VTE may be further increased by patient factors. To be clinically applicable, use of individual patient data for risk stratification must be easy to apply and sufficiently discriminative. 5 Lastly, a threshold (cutoff) of magnitude of benefit is needed to allow for consistent recommendations across different types of surgeries in different patient populations. It is with these considerations in mind that the CUA guideline panel on thromboprophylaxis chose to frame its recommendations.
Methodology

Creating a de novo guidelines vs. endorsing and/or adapting existing guidelines
The CUA guideline panel first determined if a CUA guideline is needed for VTE prophylaxis. To address this issue, three questions were posed: 1) Are perioperative VTEs a clinically relevant problem and is there uncertainty about the best prophylactic management 2) Is there variation in practice within the subject area and 3) Is currently available guidance sufficiently inadequate to require creation of a new guideline?
Applying these three questions, the panel concluded that adapting or endorsing an existing guideline would be most appropriate.
In brief, the panel believes that perioperative VTE prophylaxis is a clinically relevant problem because VTEs are associated with morbidity and mortality among patients who undergo urological surgery. [6] [7] [8] There appears to be considerable variation in VTE prophylaxis strategies in Canada and internationally. [9] [10] [11] Additionally, the CUA membership indicated a strong interest for a CUA VTE guideline in a member survey conducted by the CUA Office of Education in 2016. This survey identified VTE prophylaxis as an area of unaddressed need and, as a result, a continuing professional development teaching program was created. This program is available to CUA members on the member portal.
Regarding existing clinical guidance, the panel is aware of a number of medical, oncological, and surgical VTE guidelines, which are not urology-specific and generally do not weigh the tradeoff between VTE prevention and bleeding explicitly. 12 Most recently, the European Association of Urology (EAU) published a VTE guideline that is current and urology procedure-specific. Additionally, the EAU guideline was developed using rigorous methodology (GRADE approach) and source materials are all publicly available. 4, 13 Importantly, the EAU guideline addressed the intended scope of the CUA. In considering these factors, the panel felt it would be most appropriate to adapt or endorse the recently published EAU guideline.
14 Adopting or adapting the EAU VTE guideline for the CUA: The modified ADAPTE framework
Several methodological approaches exist to adapt or endorse an existing guideline. 15 There have not been systematic assessments of rigor, efficiency, or transparency of these methods. Two methodological frameworks appealed to the panel, given the context and desire to use the GRADE framework. [16] [17] [18] The first is the GRADE-ADOLOPMENT process, which is comprised of eight steps and has been developed specifically to adapt GRADE guidelines to local contexts. 19 The second is a modification of the original 22-step ADAPTE process simplified to five steps that was specifically designed to modify the American College of Chest Physicians thromboprophylaxis guidelines (ACCP-AT9) to specific country's context. 20, 21 The panel elected to follow the latter approach, given its simplicity and the similarities between its development and the CUA panel's objectives.
Summary of the process used to adapt EAU guideline for the Canadian context
To adapt the EAU VTE guidelines to the Canadian context, we followed a five-step process as follows: 1) planning; 2) Guideline: Postoperative VTE prophylaxis initial assessment of the recommendations; 3) modification; 4) publication; and 5) evaluation. 20, 21 The planning steps occurred after publication of the EAU guideline and underpinning meta-analyses in March 2017. 13, 14 At this time, a CUA VTE panel was convened, met in person, decided on scope, and discussed methodological elements of the guideline to be adopted. Furthermore, the panel confirmed the methodological approach to be used for adapting the EAU guideline to the Canadian context. Each panel member independently reviewed each EAU guideline, all EAU recommendations, methodology, source documents, and appendices. Each member independently assigned one of three possible actions for each of the 32 recommendations: adopt, exclude, or modify. Recommendations deemed entirely applicable to the Canadian context and without methodological concern were adopted without modification. Recommendations deemed not applicable or beyond the scope of the CUA panel's objectives were excluded. The remaining recommendations were considered for modification based on: 1) the balance between benefits and harms; 2) confidence in the estimates of the effect of the interventions under consideration; 3) extent of assumed variability in patient values and preferences; and 4) resource and health equity considerations. Additionally, new topics or concerns not covered in the EAU guideline documents were also identified for further discussion by the panel. Decisions regarding adoption, exclusion, modification, and new topics were agreed upon by panel consensus.
In summary, the panel reviewed the 32 EAU recommendations and their supporting source data. All panelists independently selected 14 of the 32 EAU recommendations for adoption without modification. These recommendations were not discussed further individually, however, they were considered when choosing how to frame recommendations and simplify the overall presentation of clinical guidance. As a result, several recommendations from the EAU guideline were combined to reduce the overall number of recommendations in the CUA document, reducing these from 14 to 11. The remaining 18 of 32 recommendations were discussed by the panel for modification or exclusion. As a result of this process, 14 recommendations were modified into seven and four were excluded. The panel excluded four recommendations because they were beyond the scope of the CUA objectives and were replaced with one clinical principle. The rationale and judgments made to justify modification of the remaining recommendations are detailed in the text of this guideline. Therefore, this CUA guideline includes 18 recommendations and one clinical principle.
Five additional topics were identified as inadequately addressed or unclear for Canadian readership within the EAU guideline. These were: 1) availability and cost of prophylactic agents in different Canadian jurisdictions; 2) explanation and justification for timing of initiation of thromboprophylaxis; 3) the role of direct-acting oral anticoagulants (DOACs) for postoperative thromboprophylaxis in urological surgery; 4) the role of perioperative tranexamic acid (TXA) to reduce bleeding; and 5) the possible association between neoadjuvant chemotherapy and VTE for patients who undergo surgery (i.e., radical cystectomy). The panel considered each topic for inclusion in the CUA guideline. The role of DOACs, TXA, and the impact of neoadjuvant chemotherapy on VTEs were felt to be important issues that should be addressed either as a separate guidance document or subsequent iteration of this guideline.
How to interpret strong and weak recommendations
The CUA guideline steering committee and CUA executive have committed to conducting and reporting CUA guidelines using the GRADE framework when possible. A detailed explanation of GRADE is outside the scope of this document, but an overview is available as a short series in the British Medical Journal, [16] [17] [18] and a more detailed elaboration in a series of methodology articles 22 (CUA GRADE reference sheet available as Supplementary Material at cuaj.ca). A webcast of the introductory CUA GRADE workshop is also available for viewing by CUA membership (http://tech4pco. com/cua/videos/cua-grade-workshop?keycode=login).
Four types of recommendations are possible in the GRADE framework: strong for, weak for, weak against, and strong against. These represent a spectrum of guidance that depends on both the relative tradeoff of good and bad outcomes and the quality of the evidence (i.e., certainty in the estimates of effect for each outcome). By convention, when a strong guidance statement is made the panel recommends a course of action. Conversely, when a weak statement is made the panel suggests a course of action.
In the context of thromboprophylaxis, the main benefit of the intervention is prevention of symptomatic VTE, and the main harm is an increased risk of major bleeding. When the balance of evidence clearly supports a benefit or harm to the tradeoff AND there is high certainty in the estimates of effect (good quality evidence, low risk of bias), a strong recommendation for or against VTE prophylaxis is made. In scenarios where there appears to be benefit or harm from an intervention, but there is less certainty in the estimates of effect, a weak recommendation for or against is made. In some scenarios, there may be high certainty in our evidence but the tradeoff is close. In these situations, we also make a weak recommendation for or against.
How to interpret and apply the CUA GRADE guidelines for VTE prophylaxis to patients A strong recommendation is one in which the large majority of patients (typically >90%) in this situation would agree with the recommended course of action. This is a situation of informed consent in which the patient accepts or declines the recommended course of action. A weak recommendation indicates there is less certainty regarding the best course of action and management is more strongly dependent on individual patient values and preferences (i.e., desire to avoid VTE complications and burden of treatment vs. desire to avoid bleeding complications). This is a situation of shared decision-making and weighing the importance of outcomes from the individual patient's point of view.
To make clear recommendations, a cutoff for the magnitude of net benefit is required. The EAU guideline proposed a cutoff for recommendation based on indirect evidence from patient values and preference studies in a population who were prescribed a low-molecular-weight heparin (LMWH) for a non-surgical reason. 23, 24 Ideally, studies evaluating the values and preferences of patients receiving LMWH as postoperative prophylaxis should be used. The CUA panel was not able to identify such a study. The panel discussed at length whether to adopt the cutoffs proposed in the EAU thromboprophylaxis guideline vs. generating a new evidence-based cutoff. The CUA panel judged that it was not feasible to complete new studies in a timely fashion, thus the panel elected to adhere to the cutoffs as described in the EAU thromboprophylaxis guideline.
14 This is an area in need of future research.
Timing and duration of pharmacological thromboprophylaxis with surgery
The goal of perioperative thromboprophylaxis is to reduce symptomatic VTEs while minimizing any increased risk of major bleeding. Major bleeding is defined as bleeding requiring re-operation, embolization, or causing death. It is therefore important to consider when VTEs and major bleeding usually manifest when considering the recommended timing and duration of thromboprophylaxis. The incidence of VTE is highest and roughly linear in the first four weeks after surgery and reduces substantially thereafter (Figs. 2, 3 ). The incidence of major bleeding is highest on the day of surgery and decreases rapidly over the next five days (Fig. 3) . Therefore, one strategy to improve the net benefit of guideline recommendations is to recommend starting prophylaxis after the period of highest bleeding risk and continue prophylaxis for the duration of highest VTE risk. This strategy may slightly increase the short-term incidence VTE, but should also decrease major bleeding episodes by a greater amount since most bleeding will occur on the day of surgery.
Recommendations for use of VTE prophylaxis in urological surgery
The following recommendations apply to the use of LMWH as a prophylactic agent, starting the morning after surgery and continuing for 28 days as compared to not giving any pharmacological prophylaxis.
VTE and bleeding risks depend on patient factors and surgical factors. Recommendations presented below are for specific surgery types accounting for the tradeoff of symptomatic VTE (DVT, PE, or death from VTE) and major bleeding (requiring re-operation, embolization, or death) for specific surgeries. The impact of surgery on VTE risk is affected by patient-level factors. Recommendations below refer to a patient risk stratification for VTE as proposed by Tikkinen et al and adopted by the EAU. 4 This risk stratification summarizes the most compelling patient-level risk factors based on data from other models of VTE risk, including Caprini, Rogers, Panucci, and large population-based studies. 4 Four factors were identified with associated relative increase in VTE risk, as shown in Table 1 . Judgment: In Canada, radical cystectomy is predominantly an open procedure for which higher-quality evidence was available; therefore, the panel felt confident in making a strong recommendation. Regarding robotic approach, the estimated effects for bleeding and VTE were very similar and parallel those for the open procedure, from which we infer that net benefit will likely remain similar between two approaches despite lower certainty in estimates (low-quality evidence) for the robotic approach.
Radical prostatectomy
Radical prostatectomy is a procedure in which the dissection may vary by the perceived severity of prostate cancer treated. As such, the panel recognizes that significant differences in procedure may occur when treating less aggressive or more aggressive disease. The extent of lymph node dissection performed may increase with the severity of disease and this factor also increases VTE risk. Therefore, recommendations for prophylaxis are additionally stratified by extent of lymph node dissection, as well as patient and procedure type. Extent of lymph node dissection is stratified as follows: no lymph node dissection; standard dissection (node of Cloquet, along external iliac vein up to the bifurcation of the internal and external iliac, obturator fossa); extended dissection (standard dissection and dissection above bifurcation of iliac vessels or including presacral, precaval, or preaortic nodes). who undergo open prostatectomy with no lymph node dissection or standard dissection, the net benefit only weakly favours giving thromboprophylaxis due to close tradeoff of harms and benefit. We considered combining Recommendations 2 and 3, but recognize that there may be a substantial proportion of patients with few risk factors who undergo prostatectomy with a standard lymph node dissection and the decision may be value-sensitive for some patients in this context. (weak recommendation, low-quality evidence). Judgement: Recommendations for laparoscopic and robotic approach were combined to simplify guideline reporting and reduce the number of recommendations. We recognize that estimate of effect for bleeding and VTE may vary considerably for these two procedures 13 and we did not attempt to combine these. We recognized that the net benefit for either laparoscopic or robotic prostatectomy led to the same recommendations in all but one situation of a high-risk patient undergoing a standard pelvic lymph node dissection (PLND). In this instance, the difference in net benefit was 10/1000 as compared to 6.3/1000 for laparoscopic and robotic approaches, respectively, which did not change the direction of recommendation but only the strength. As a panel, given the borderline value of 10/1000, we chose to place a higher value on encouraging explicit discussion of patient values and preferences and made a weak recommendation for prophylaxis in this situation.
Open radical prostatectomy without an extended lymphadenectomy
Open radical prostatectomy with extended lymph node dissection
Robotic or laparoscopic radical prostatectomy
Open renal surgery for cancer
Recommendation 7:
For patients undergoing open radical or partial nephrectomy or nephroureterectomy, we suggest use of pharmacological thromboprophylaxis (weak recommendation, very low-to low-quality evidence) and mechanical prophylaxis (weak recommendation, lowquality evidence). (weak recommendation, low-quality evidence). For patients undergoing laparoscopic nephroureterectomy: Judgment: Laparoscopic nephroureterectomy was not evaluated in the EAU VTE guideline due to lack of data. We performed an updated literature search but failed to identify compelling series that reported VTE and bleeding outcomes, as well as proportion of prophylaxis use. In the Canadian context, we believe that a large number of nephroureterectomies are performed laparoscopically with open bladder cuff or entirely laparoscopically. We felt that it was not feasible at this time to generate a de novo recommendation for this procedure. In the absence of data, we suggest to follow Recommendation 8 for patients undergoing laparoscopic nephroureterectomy.
Laparoscopic renal surgery for cancer
Robotic renal surgery for cancer
Recommendation 10: For patients who are undergoing robotic partial nephrectomy:
-At low risk of VTE, we suggest against use of pharmacological prophylaxis (weak recommendation, moderate-quality evidence). -At moderate risk of VTE, we suggest use of pharmacological prophylaxis (weak recommendation, moderate quality-evidence). -At high risk, we recommend use of pharmacological prophylaxis (strong recommendation, moderatequality evidence). -Mechanical prophylaxis is suggested for all patients (weak recommendation, low-quality evidence). Judgment: The panel recognizes that some Canadian urologists may perform radical nephrectomy or nephroureterectomy by robotic approach, but we believe that this is a minority. Use of thromboprophylaxis for these procedures is not well-reported in the literature. In the absence of data, we suggest following Recommendation 8 for these procedures. We recommend that if there is increased use of robotic radical nephrectomy or nephroureterectomy in Canada that this decision is revisited in future iterations of this guideline.
Retroperitoneal lymph node dissection (RPLND)
Recommendation 11: For all patients undergoing RPLND for testicular germ cell tumour, we suggest use of pharmacological prophylaxis (weak recommendation, very low-quality evidence) and suggest use of mechanical prophylaxis (weak recommendation, low-quality evidence).
Judgment: The panel recognizes that post-chemo RPLND likely has higher VTE risk and possibly higher bleeding risk Guideline: Postoperative VTE prophylaxis than primary RPLND. However, this procedure is infrequently performed and, as such, there is a paucity of reliable data from which to derive estimates of effect for these outcomes. The independent effect of exposure to cisplatin chemotherapy may be calculable, but for pragmatic reasons was felt not to be within the scope of the current iteration of this guideline. We suggest these situations be considered on a case-by-case basis. Until better data emerges, it may be reasonable to apply guidance for primary RPLND to the post-chemo setting.
II. VTE prophylaxis recommendations for non-oncological urological surgery
Recommendation 12: For all patients undergoing ambulatory day surgery who are not admitted to hospital, regardless of individual patient VTE risk, we recommend against use of pharmacological prophylaxis (strong recommendation, moderate-quality evidence) and suggest against use of mechanical prophylaxis (weak recommendation, lowquality evidence).
Judgment: The panel believes that incidence of VTE in this population is sufficiently low that it is unlikely attributable to surgical intervention rather than baseline risk of VTE; however, risk of bleeding will be elevated, typically by a very small magnitude, regardless of surgery. Therefore, in all cases, extended prophylaxis is not warranted. Recommendation 13: For all patients who undergo transurethral resection of the prostate (TURP), we suggest against use of pharmacological prophylaxis (weak recommendation, very low-quality evidence) and we suggest against use of mechanical prophylaxis (weak recommendation, very lowquality evidence).
Judgment: We placed a higher value on making fewer recommendations in an attempt to facilitate clinical uptake of this guideline than the very borderline improvement in net benefit (2.9 per 1000 where a priori cutoff was 2.5 per 1000) among patients at high risk for VTE undergoing TURP. Therefore, we suggest against use of mechanical prophylaxis in all patients undergoing TURP rather than making separate recommendations for high-risk patients. Recommendation 14: For patients undergoing donor nephrectomy for transplantation or nephrectomy for benign disease or recipient transplant:
-At low or moderate risk of VTE, we suggest against use of pharmacological prophylaxis (weak recommendation, very low-to low-quality evidence) without mechanical prophylaxis. -At high risk of VTE, we suggest the use of pharmacological prophylaxis (weak recommendation, very lowto low-quality evidence) and mechanical prophylaxis (weak recommendation, low-quality evidence). Judgment: This does not preclude the use of anticoagulation for other reasons, such as graft thrombosis, which are outside of the scope of this recommendation.
Recommendation 15:
For all patients undergoing surgery for continence or prolapse, we suggest against the use of pharmacological prophylaxis (weak recommendation, very low-to low-quality evidence) and suggest against use of mechanical prophylaxis (weak recommendation, low-quality evidence).
Recommendations for bridging of anticoagulation and antiplatelet agents
Guidance below is intended to inform Canadian urologists about best practice for common situations. The panel recognizes that in many cases, perioperative management of anticoagulation may require a multidisciplinary approach, which may include hematology, internal medicine, or cardiology. The panel recommends the treating urologist consider each patient scenario individually to determine appropriate management and consider consultation with a physician with expertise in thrombosis for any patient encounter that is not standard.
Definition
Patients are considered to be at very high risk of thrombosis if any one of the following are present:
-Drug-eluting stent placement within six months; -Bare metal stent placement within six weeks; -Transient ischemic attack (TIA) stroke within 30 days; -New incidence of VTE within one month; -Severe thrombophilia (such as antithrombin deficiency, antiphospholipid antibody, or other as identified by appropriate specialist); -Cage-ball mechanical heart valves. Recommendation 16: In patients receiving an antiplatelet agent who do not have a very high risk of thrombosis (see definition) the panel recommends stopping antiplatelet agents seven days prior to surgery without bridging (strong recommendation, high-quality evidence) and restarting antiplatelet therapy four days post-surgery as compared to a longer period off therapy (strong recommendation, moderate-quality evidence). Recommendation 17: In patients receiving an anticoagulant agent who do not have very high risk of thrombosis (see definition), the panel recommends stopping prior to surgery without bridging therapy (strong recommendation, high-quality evidence) and restarting four days post-surgery as compared to a longer period off therapy (strong recommendation, moderate-quality evidence). The recommended duration off anticoagulation prior to surgery varies by therapy as follows:
-DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) three days prior;
-Warfarin five days prior; -LMWH (therapeutic dosing) 12 hours (if twice daily dosing) or 24 hours (if once daily dosing) prior; -Fondaparinux 24 hours prior. Note: Renal function may affect DOAC clearance and prolong anticoagulant activity. For patients with impaired renal function, DOAC may need to be stopped longer than three days prior to surgery. The panel elected to modify the timing of stopping anticoagulant or antiplatelet agents to be consistent with guidance from Thrombosis Canada. 25 Additionally, the PAUSE study (https://clinicaltrials.gov/ ct2/show/NCT02228798), once results are reported, may provide important information on the optimal timing of stopping DOAC and should be addressed in subsequent iterations of this guideline. Recommendation 18: Patients at very high risk of thrombosis in whom surgery can be delayed until the period of very high risk is completed should have surgery delayed until the period of very high risk is over (strong recommendation, high-quality evidence).
Clinical principle: For patients at very high risk of thrombosis in whom surgery cannot be delayed, our panel recommends multidisciplinary discussion and an individualized treatment plan.
Judgment: The panel is of the opinion that a situation in which patients are at very high risk of thrombosis and surgery cannot be delayed will be rare and benefit from involvement of multiple specialties and patient values and preferences to weigh risks and benefits of a tailored management approach. We felt that it was not within the scope of Canadian urological practice to proceed in these situations without further consultations with specialists from appropriate disciplines.
Limitations, further research, and subsequent iterations of this guideline
In completing the modified ADAPTE process for this guideline, the panel has identified several areas in need of further research to improve subsequent iterations and contribute to the field of perioperative thromboprophylaxis in general. Many recommendations are weak for two reasons: due to limitations in the quality of the body of evidence available for outcomes related to some procedures, and/or due a close tradeoff of benefits and harms for other situations. These limitations highlight a clinical research domain in need of more attention to improve the quantity and quality of data available to direct best care. Specifically, there is a need for more published surgical series that include data on thromboprophylaxis use and outcomes (including VTE and bleeding), especially for procedures not covered in this guideline.
Additionally, weighing the net benefit of close tradeoffs is highly dependent on patient values and preferences. Different stakeholders may view different magnitudes of net benefit as sufficient to recommend use of prophylaxis. The current recommendations have a clinical emphasis and attempt to account for patient values and preferences in determining sufficient magnitude of net benefit for a strong recommendation (10 per 1000). However, due to the paucity of evidence available on patient values and preferences in this area, indirect evidence from a different patient population was used rather than the postoperative surgical patient. Improved estimates of patient values and preferences may impact the strength and direction of recommendations in future iterations of this guideline.
The optimal timing and duration of prophylaxis is also controversial and based on very little direct evidence. Recommendations in this CUA guideline are based on modelling studies of large data sets that are consistent with the published literature. However, direct comparisons of the effect of pharmacological prophylaxis before and after surgery are not available. We base our judgment on the relative merit of reducing bleeding on the day of surgery to the increase in VTE risk during this period. While the panel felt this was a reasonable consideration of the tradeoffs of bleeding and VTE, direct evidence from randomized studies would strengthen our certainty in this assumption. Additionally, the approach to patient-level risk stratification adopted by the panel is a consequence of the approach used to value the tradeoff between bleeding and VTE based on procedure-specific baseline risks. A procedure-specific baseline risk accounts for procedure-specific variables, such as "pelvic surgery" or "presence of malignancy." Therefore, a risk stratification of pertinent patient factors was used rather than a risk-stratification approach that uses both patient and procedure factors, such as Caprini. 2, 5 Consequently, this risk-stratification approach has not been tested empirically. Future iterations of this guideline will benefit from validation studies of the EAU patient risk-stratification approach.
Lastly, thrombosis research is a rapidly changing field, with newer agents emerging as reasonable alternatives, most of which have yet to be evaluated in the urological context. It is our hope that subsequent CUA guidance on thromboprophylaxis will also consider the role of DOACs and TXA in striking the right balance to minimize bleeding and reduce thrombosis.
Competing interests: Dr. Violette has been a speaker for Janssen and Sanofi. (He stopped accepting honoraria in 2017 and only presents his own material, but events have been organized by industry). Dr. Lavallée has participated in advisory board meetings for Ferring and Sanofi, and has received a grant from Sanofi. Dr. Kassouf has received grants and/or honoraria from Astellas, AstraZeneca, Janssen, Merck, and Roche. Dr. Gross has attended advisory board meetings for Leo and Pfizer; has received speakers fees from Bayer, BMS, Leo, Pfizer, and Servier; has received research grants from BMS, Boehringer-Ingelheim, and Pfizer; and has participated in clinical trials supported by Bayer, BMS, Pfizer, and Servier. Dr. Shayegan has received grants and/or honoraria from Abbvie, Astellas, Janssen, and Sanofi, and has participated in clinical trials supported by Astellas and Janssen. This paper has been peer-reviewed.
